Dear Investor Friends:
Please join us for this virtual investor-only meeting on Friday, December 19 featuring Intrommune, a consumer health company with a revolutionary approach to peanut allergy prevention.
Intrommune’s patented platform delivers allergens via a familiar routine: brushing your teeth. This toothpaste trains the immune system and helps prevent life-threatening nut allergies.
The Investment Opportunity:
Amount: $4 million, first closing in December/January
Minimum investment: $100,000
Early investors receive preferential terms
NASDAQ IPO targeted within 36 months
Key Investment Considerations:
Validated Science, Consumer Simplicity - In the Phase 1 study for peanut allergy, patients achieved 97% adherence with 0 dropouts and 0 cases of anaphylaxis
TRACTION - Company is already generating revenue through its distribution channels in November, 2025.
Enormous Market Need with 1st Mover Advantage - Over 33 million Americans suffer from food allergies, with limited treatment options. Intrommune is the only biotech-grade product in a consumer-ready delivery formar.
Attractive Investment Terms - Attractive valuation and terms with incentives.
World Class Leadership - Company is led by some of the top names in the industry
Event Details:
Location: Online via Zoom
Date: Friday, December 19 | 11:30am EST
Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.
Don't miss out - RSVP now.
You can request investment materials by contacting Skylar Rallison at srallison@opus8.com
We look forward to hosting you and exploring this rare convergence of biotech innovation and consumer-scale opportunity.
All the best,
Tien Wong
CEO
Opus8, Inc.